Uniqure NV(QURE)stock report

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Finance:
Market Cap:2900M; Shares Outstanding:43.6M; Short Interest: 11.91%; Q3 2019(9/30/19): Cash 403M. Loss 23.61M

EPS and Sales:
https://finance.yahoo.com/quote/QURE/financials?p=QURE

Date EPS % last year % last quarter
2018.12.31 -2.34 20.41% 33.71%
2019.3.31 -0.74 -25.42% 68.38%
2019.6.30 -1.57 -35.34% -9.00%
2019.9.30 -2.14 -22.29% -36.31%

 

Date Sales % last year % last quarter
2018.12.31 11.28M -13.91% 14.18%
2019.3.31 1.14M -67.34% -89.89%
2019.6.30 3.61M -44.70% 216.67%
2019.9.30 4.66M -51.88% 29.09%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=QURE&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/QURE/institutional-ownership/

2019.12.12:
Total institutions: 189,no change
Shares hold: 33718.3k shares. no change
shares% hold: 77.30%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/QURE/price-targe

Leave a Reply